A prospective study of leukemic transformation control and hematopoietic recovery in patients with myelodysplastic syndrome(MDS) receiving iron chelation therapy with deferasirox(Exjade)
Not Applicable
- Conditions
- Myelodysplastic syndome
- Registration Number
- JPRN-UMIN000003365
- Lead Sponsor
- Division of Hematology, Department of Medicine, Showa University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1, heavy renal and liver disorder. 2, during pregnancy, the lactation period. 3, allergy to Deferasirox 4, The case who cannot receive informed consent from patients. 5, The patients who received chemotherapy, except for oral chemoterapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The marker about iron overload once three months. Bone marrow aspiration after one year.
- Secondary Outcome Measures
Name Time Method